CMS issues permanent J-code for Vyjuvek

Vyjuvek, the first FDA-approved treatment for dystrophic epidermolysis bullosa, has received a permanent J-code from the Centers for Medicare and Medicaid Services, Krystal Biotech announced in a press release.
The J-code simplifies billing and reimbursement for Vyjuvek (beremagene geperpavec-svdt), a herpes simplex virus type 1 vector-based gene therapy indicated in the treatment of epidermolysis bullosa wounds.
“The permanent J-code will help ensure efficient and accurate reimbursement of Vyjuvek and further enable us to bring this important treatment to DEB patients in need,”

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.